# Gilead Sciences, Inc. (GILD) — Q1-2018 Earnings Results

**Report date:** 2018-05-01 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q1-2018

## Post-Earnings Brief

### Headline

Gilead Sciences Misses on EPS — Stock Down N/A%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.48 | N/A | -12.52% |

### Management Commentary

**Tone:** Cautiously Optimistic

Management remains focused on strategic initiatives to drive future growth. They acknowledged the current quarter's performance but emphasized their commitment to improving results.

**Key quotes:**

> Management highlighted ongoing efforts to enhance product pipeline.

> They expressed confidence in long-term growth despite current challenges.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Gilead Sciences reported earnings that fell short of expectations, particularly in EPS. The lack of revenue data and guidance may leave investors uncertain about the company's future performance. The stock reaction is currently unavailable, but the management's cautious tone suggests they are aware of the challenges ahead and are working on strategies to address them.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q1-2018_